SynBioBeta Speaker
Roya Amini-Naieni
Trilobio
CEO & Co-founder
Roya Amini-Naieni is the CEO and Co-Founder of Trilobio, a robotics and biology research platform with the mission to fully automate biology for everyone. Roya studied Mathematics and Computational Biology at Harvey Mudd College (HMC) where she founded a SynBio lab with grant funding from HMC's president. Previously, she conducted SynBio research at University of Washington, HMC and at Asimov, a leading SynBio startup. Roya also founded the first non-collegiate iGEM team in WA state. She is a 776 Fellow and Forbes 30 Under 30 recipient.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Roya
This Year
•
-
Tools & Tech
Self-Driving Labs, AI, and Automation: A Practical Guide to Getting Started
AI-enabled, self-driving labs are still emerging, but their foundations are already transforming how teams design, run, and interpret experiments. This session offers a practical guide for scientists and R&D leaders who want to understand what can be done today — from tightening design–test–learn loops to reducing manual error and capturing early benefits of autonomous experimentation. Rather than presenting an unrealized future, speakers will focus on practical, real-world steps that give organizations a competitive edge as SDL capabilities evolve and mature. Speakers will explore what’s working, what’s not, and how autonomous lab systems are reshaping protein engineering, pathway optimization, and therapeutic design.
Get a Ticket
•
-
Tools & Tech
Self-Driving Labs, AI, and Automation: A Practical Guide to Getting Started
AI-enabled, self-driving labs are still emerging, but their foundations are already transforming how teams design, run, and interpret experiments. This session offers a practical guide for scientists and R&D leaders who want to understand what can be done today — from tightening design–test–learn loops to reducing manual error and capturing early benefits of autonomous experimentation. Rather than presenting an unrealized future, speakers will focus on practical, real-world steps that give organizations a competitive edge as SDL capabilities evolve and mature. Speakers will explore what’s working, what’s not, and how autonomous lab systems are reshaping protein engineering, pathway optimization, and therapeutic design.
Get a Ticket
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
